Buy Docusign as Paper Loses Luster in Covid Times

This post was originally published on this site — It’s time to sign up for DocuSign Inc (NASDAQ:DOCU). 

Shares are up 5% on Monday after Morgan Stanley (NYSE:MS) upgraded the stock to overweight from equalweight.

A recent pullback makes the investment story compelling, and Covid-driven changes to business structure are likely to be more lasting than originally expected, analyst Stan Zlotsky said, according to StreetInsider. 

Morgan Stanley set a conservative price target of $260, citing “very healthy renewal rates (customers won’t return to paper processes after going digital).” Docusign also has a dominant competitive position, and the analyst sees “an opportunity for multiple expansion from here.”

The firm had downgraded the shares earlier this year when the stock was trading at a 10% premium to peers. 

Shares have 10 buy ratings, six holds and no sells. The stock is up more than 200% for 2020 and is currently trading around $229.28.

Add Comment